RU2006118359A - Комбинации для лечения вирусного гепатита с (hcv) - Google Patents
Комбинации для лечения вирусного гепатита с (hcv) Download PDFInfo
- Publication number
- RU2006118359A RU2006118359A RU2006118359/15A RU2006118359A RU2006118359A RU 2006118359 A RU2006118359 A RU 2006118359A RU 2006118359/15 A RU2006118359/15 A RU 2006118359/15A RU 2006118359 A RU2006118359 A RU 2006118359A RU 2006118359 A RU2006118359 A RU 2006118359A
- Authority
- RU
- Russia
- Prior art keywords
- inhibitor
- hepatitis
- virus
- cytochrome
- monooxygenase
- Prior art date
Links
- 208000010710 hepatitis C virus infection Diseases 0.000 title claims abstract 3
- 208000005176 Hepatitis C Diseases 0.000 title abstract 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims abstract 20
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims abstract 20
- 208000003311 Cytochrome P-450 Enzyme Inhibitors Diseases 0.000 claims abstract 17
- 241000711549 Hepacivirus C Species 0.000 claims abstract 17
- 238000000034 method Methods 0.000 claims abstract 16
- 239000000203 mixture Substances 0.000 claims abstract 10
- 239000003112 inhibitor Substances 0.000 claims abstract 9
- 108700012707 hepatitis C virus NS3 Proteins 0.000 claims abstract 7
- 150000003839 salts Chemical class 0.000 claims 10
- 108010044467 Isoenzymes Proteins 0.000 claims 6
- 229940122280 Cytochrome P450 inhibitor Drugs 0.000 claims 5
- 239000002552 dosage form Substances 0.000 claims 3
- 102000018832 Cytochromes Human genes 0.000 claims 2
- 108010052832 Cytochromes Proteins 0.000 claims 2
- 102000008109 Mixed Function Oxygenases Human genes 0.000 claims 2
- 108010074633 Mixed Function Oxygenases Proteins 0.000 claims 2
- 101150053185 P450 gene Proteins 0.000 claims 2
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 claims 2
- 239000003443 antiviral agent Substances 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 229960000311 ritonavir Drugs 0.000 claims 2
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical group N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 claims 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 claims 1
- 101100497953 Arabidopsis thaliana CYP22 gene Proteins 0.000 claims 1
- PCLITLDOTJTVDJ-UHFFFAOYSA-N Chlormethiazole Chemical compound CC=1N=CSC=1CCCl PCLITLDOTJTVDJ-UHFFFAOYSA-N 0.000 claims 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 1
- 108010036949 Cyclosporine Proteins 0.000 claims 1
- 108010074922 Cytochrome P-450 CYP1A2 Proteins 0.000 claims 1
- 108010026925 Cytochrome P-450 CYP2C19 Proteins 0.000 claims 1
- 108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 claims 1
- 108010001202 Cytochrome P-450 CYP2E1 Proteins 0.000 claims 1
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 claims 1
- 208000009011 Cytochrome P-450 CYP3A Inhibitors Diseases 0.000 claims 1
- 102100026533 Cytochrome P450 1A2 Human genes 0.000 claims 1
- 102100029363 Cytochrome P450 2C19 Human genes 0.000 claims 1
- 102100021704 Cytochrome P450 2D6 Human genes 0.000 claims 1
- 102100024889 Cytochrome P450 2E1 Human genes 0.000 claims 1
- 102100039205 Cytochrome P450 3A4 Human genes 0.000 claims 1
- 102000006992 Interferon-alpha Human genes 0.000 claims 1
- 108010047761 Interferon-alpha Proteins 0.000 claims 1
- 102000003996 Interferon-beta Human genes 0.000 claims 1
- 108090000467 Interferon-beta Proteins 0.000 claims 1
- 102000008070 Interferon-gamma Human genes 0.000 claims 1
- 108010074328 Interferon-gamma Proteins 0.000 claims 1
- 108060004795 Methyltransferase Proteins 0.000 claims 1
- 108091005804 Peptidases Proteins 0.000 claims 1
- 239000004365 Protease Substances 0.000 claims 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical group N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims 1
- 102000007501 Thymosin Human genes 0.000 claims 1
- 108010046075 Thymosin Proteins 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 101000998548 Yersinia ruckeri Alkaline proteinase inhibitor Proteins 0.000 claims 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims 1
- 229960003805 amantadine Drugs 0.000 claims 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 229960001265 ciclosporin Drugs 0.000 claims 1
- 229960004414 clomethiazole Drugs 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 229930182912 cyclosporin Natural products 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- RIKMMFOAQPJVMX-UHFFFAOYSA-N fomepizole Chemical compound CC=1C=NNC=1 RIKMMFOAQPJVMX-UHFFFAOYSA-N 0.000 claims 1
- 229960004285 fomepizole Drugs 0.000 claims 1
- 229940044627 gamma-interferon Drugs 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 229960004125 ketoconazole Drugs 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 239000003475 metalloproteinase inhibitor Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229960000329 ribavirin Drugs 0.000 claims 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims 1
- 210000003705 ribosome Anatomy 0.000 claims 1
- IQFYYKKMVGJFEH-CSMHCCOUSA-N telbivudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1O[C@@H](CO)[C@H](O)C1 IQFYYKKMVGJFEH-CSMHCCOUSA-N 0.000 claims 1
- 229960005311 telbivudine Drugs 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 claims 1
- LQCLVBQBTUVCEQ-QTFUVMRISA-N troleandomycin Chemical compound O1[C@@H](C)[C@H](OC(C)=O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](C)C(=O)O[C@H](C)[C@H](C)[C@H](OC(C)=O)[C@@H](C)C(=O)[C@@]2(OC2)C[C@H](C)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)OC(C)=O)[C@H]1C LQCLVBQBTUVCEQ-QTFUVMRISA-N 0.000 claims 1
- 229960005041 troleandomycin Drugs 0.000 claims 1
- 230000000840 anti-viral effect Effects 0.000 abstract 1
- 230000002452 interceptive effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2292—Thymosin; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Chemical Or Physical Treatment Of Fibers (AREA)
- Catalysts (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Claims (21)
1. Фармацевтическая композиция, содержащая ингибитор NS3/4A протеазы вируса гепатита С или его фармацевтически приемлемую соль, ингибитор цитохром Р450-монооксигеназы или его фармацевтически приемлемую соль, и фармацевтически приемлемый носитель.
2. Композиция по п. 1, где ингибитор NS3/4A протеазы вируса гепатита С представляет собой VX-950 или его стереоизомер.
3. Композиция по п. 1, где ингибитор NS3/4A протеазы вируса гепатита С представляет собой VX-950.
4. Композиция по любому из пп. 1-3, где ингибитор цитохрома Р450 представляет собой ингибитор изофермента 3А4 ("CYP3A4"), изофермента 2С19 ("CYP2С19"), изофермента 2D6 (("CYP2D6"), изофермента 1А2 ("CYP1А2"), изофермента 2С9 ("CYP2С9") или изофермента 2Е1 ("CYP2Е1").
5. Композиция по любому из пп. 1-3, где ингибитор цитохрома Р450 представляет собой ритонавир, кетоконазол, тролеандомицин, 4-метилпиразол, циклоспорин и клометиазол.
6. Композиция по любому из пп. 1-3, где ингибитор цитохрома Р450 представляет собой ингибитор CYP3А4.
7. Композиция по любому из пп. 1-3, где ингибитор цитохрома Р450 представляет собой ритонавир.
8. Способ повышения биологической доступности ингибитора NS3/4A протеазы вируса гепатита С у пациента, включающий введение пациенту композиции по любому из пп. 1-7.
9. Способ лечения или профилактики инфекции вируса гепатита С у пациента, включающий введение пациенту ингибитора NS3/4A протеазы вируса гепатита С или его фармацевтически приемлемой соли, и ингибитора цитохром Р450-монооксигеназы или его фармацевтически приемлемой соли.
10. Способ повышения биологической доступности ингибитора NS3/4A протеазы вируса гепатита С у пациента, включающий введение пациенту ингибитора NS3/4A протеазы вируса гепатита С или его фармацевтически приемлемой соли, и ингибитора цитохром Р450-монооксигеназы или его фармацевтически приемлемой соли.
11. Способ повышения концентраций в печени ингибитора NS3/4A протеазы вируса гепатита С у пациента, включающий введение пациенту ингибитора NS3/4A протеазы вируса гепатита С или его фармацевтически приемлемой соли, и ингибитора цитохром Р450-монооксигеназы или его фармацевтически приемлемой соли.
12. Способ повышения концентраций в крови ингибитора NS3/4A протеазы вируса гепатита С у пациента, включающий введение пациенту ингибитора NS3/4A протеазы вируса гепатита С или его фармацевтически приемлемой соли, и ингибитора цитохром Р450-монооксигеназы или его фармацевтически приемлемой соли.
13. Способ по любому из пп. 9-12, где ингибитор NS3/4A протеазы вируса гепатита С и ингибитор цитохром Р450-монооксигеназы находятся в раздельных дозированных формах.
14. Способ по п. 13, где раздельные дозированные формы вводятся почти одновременно.
15. Способ по любому из пп. 9-12, где соединение и ингибитор цитохром Р450-монооксигеназы находятся в одной дозированной форме.
16. Способ по любому из пп. 8-12, где указанный способ включает введение дополнительного агента, выбранного из иммуномодулирующего агента, противовирусного агента, другого ингибитора NS3/4A протеазы вируса гепатита С, ингибитора мишени в жизненном цикле вируса гепатита С, отличной от NS3/4A протеазы, ингибитора внутреннего рибосомального входа, ингибитора широкого спектра вирусов, другого ингибитора цитохрома Р-450, или их комбинаций.
17. Способ по п. 16, где указанный иммуномодулирующий агент представляет собой α-, β- или γ-интерферон или тимозин; противовирусный агент представляет собой рибавирин, амантадин или телбивудин; или ингибитор другой мишени в жизненном цикле вируса гепатита С представляет собой ингибитор геликазы, полимеразы или металлопротеазы вируса гепатита С.
18. Способ получения композиции, содержащей ингибитор NS3/4A протеазы вируса гепатита С и ингибитор цитохром Р450-монооксигеназы, включающий стадию смешивания ингибитора NS3/4A протеазы вируса гепатита С и ингибитора цитохром Р450-монооксигеназы.
19. Терапевтическая комбинация, включающая ингибитор NS3/4A протеазы вируса гепатита С и ингибитор цитохром Р450-монооксигеназы.
20. Фармацевтическая упаковка, включающая ингибитор NS3/4A протеазы вируса гепатита С, ингибитор цитохром Р450-монооксигеназы и информационный вкладыш, содержащий указания по применению ингибиторов.
21. Набор, включающий ингибитор NS3/4A протеазы вируса гепатита С и ингибитор цитохром Р450-монооксигеназы.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51485303P | 2003-10-27 | 2003-10-27 | |
| US60/514,853 | 2003-10-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2006118359A true RU2006118359A (ru) | 2007-12-10 |
Family
ID=34549356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006118359/15A RU2006118359A (ru) | 2003-10-27 | 2004-10-27 | Комбинации для лечения вирусного гепатита с (hcv) |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US20060003942A1 (ru) |
| EP (1) | EP1677827B1 (ru) |
| JP (1) | JP2007509950A (ru) |
| KR (1) | KR20060120162A (ru) |
| CN (1) | CN1893978A (ru) |
| AT (1) | ATE416789T1 (ru) |
| AU (1) | AU2004285503A1 (ru) |
| BR (1) | BRPI0415935A (ru) |
| CA (1) | CA2543696A1 (ru) |
| CY (1) | CY1110176T1 (ru) |
| DE (1) | DE602004018363D1 (ru) |
| DK (1) | DK1677827T3 (ru) |
| ES (1) | ES2319775T3 (ru) |
| IL (1) | IL175211A0 (ru) |
| MX (1) | MXPA06004723A (ru) |
| NO (1) | NO20062428L (ru) |
| PL (1) | PL1677827T3 (ru) |
| PT (1) | PT1677827E (ru) |
| RU (1) | RU2006118359A (ru) |
| SI (1) | SI1677827T1 (ru) |
| WO (1) | WO2005042020A2 (ru) |
| ZA (1) | ZA200603863B (ru) |
Families Citing this family (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ335276A (en) | 1996-10-18 | 2000-09-29 | Vertex Pharma | Inhibitors of serine proteases, particularly hepatitis C virus (HCV) NS3 (Non Structural Protein 3) protease |
| SV2003000617A (es) * | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
| US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
| US8377952B2 (en) * | 2003-08-28 | 2013-02-19 | Abbott Laboratories | Solid pharmaceutical dosage formulation |
| PE20050374A1 (es) | 2003-09-05 | 2005-05-30 | Vertex Pharma | Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc |
| WO2005123076A2 (en) * | 2004-06-08 | 2005-12-29 | Vertex Pharmaceuticals, Inc. | Pharmaceutical compositions |
| WO2006130553A2 (en) * | 2005-06-02 | 2006-12-07 | Schering Corporation | Hcv protease inhibitors |
| EP2402331A1 (en) * | 2005-08-02 | 2012-01-04 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
| US8399615B2 (en) | 2005-08-19 | 2013-03-19 | Vertex Pharmaceuticals Incorporated | Processes and intermediates |
| US7964624B1 (en) | 2005-08-26 | 2011-06-21 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
| AR055395A1 (es) * | 2005-08-26 | 2007-08-22 | Vertex Pharma | Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c |
| CN101489557B (zh) | 2006-02-27 | 2013-12-18 | 弗特克斯药品有限公司 | 包含vx-950的共晶体和包含所述共晶体的药物组合物 |
| MX2008011429A (es) * | 2006-03-06 | 2008-09-18 | Abbott Lab | Composiciones y metodos de uso de ritonavir para tratar hcv. |
| NZ571280A (en) | 2006-03-16 | 2011-10-28 | Vertex Pharma | Deuterated hepatitis C protease inhibitors |
| JP2009530415A (ja) * | 2006-03-20 | 2009-08-27 | バーテックス ファーマシューティカルズ インコーポレイテッド | 医薬組成物 |
| CA2647158C (en) * | 2006-03-23 | 2012-07-31 | Schering Corporation | Combinations of hcv protease inhibitor(s) and cyp3a4 inhibitor(s), and methods of treatment related thereto |
| BRPI0710878A2 (pt) | 2006-04-11 | 2015-03-31 | Novartis Ag | Compostos orgânicos e seus usos |
| WO2007149382A2 (en) * | 2006-06-19 | 2007-12-27 | The Cleveland Clinic Foundation | Therapeutic compositions and methods useful in treating hepatitis |
| CN103275033B (zh) | 2006-07-07 | 2015-04-29 | 吉里德科学公司 | 治疗剂的药代动力学特性调节剂 |
| EP2112925A4 (en) * | 2006-11-15 | 2013-01-09 | Abbott Lab | SOLID PHARMACEUTICAL DOSAGE FORMULATIONS |
| JP2010519329A (ja) * | 2007-02-27 | 2010-06-03 | バーテックス ファーマシューティカルズ インコーポレイテッド | セリンプロテアーゼ阻害剤 |
| EA200970806A1 (ru) * | 2007-02-27 | 2010-08-30 | Вертекс Фармасьютикалз Инкорпорейтед | Сокристаллы и содержащие их фармацевтические композиции |
| JP5393665B2 (ja) * | 2007-07-06 | 2014-01-22 | ギリアード サイエンシーズ， インコーポレイテッド | 治療剤の薬物動態特性の調整剤 |
| EP2185546B1 (en) * | 2007-08-30 | 2011-10-26 | Vertex Pharmceuticals Incorporated | Co-crystals and pharmaceutical compositions comprising the same |
| US20090082366A1 (en) * | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched telaprevir |
| EP2205584A1 (en) * | 2007-10-10 | 2010-07-14 | Novartis Ag | Spiropyrrolidines and their use against hcv and hiv infection |
| US20100021540A1 (en) * | 2008-02-28 | 2010-01-28 | Abbott Laboratories | Tablets and Preparation Thereof |
| EP2367824B1 (en) | 2008-12-23 | 2016-03-23 | AbbVie Inc. | Anti-viral derivatives of pyrimidine |
| CN102245604A (zh) | 2008-12-23 | 2011-11-16 | 雅培制药有限公司 | 抗病毒化合物 |
| WO2010091413A1 (en) * | 2009-02-09 | 2010-08-12 | Enanta Pharmaceuticals, Inc. | Linked dibenzimidazole derivatives |
| US8314135B2 (en) * | 2009-02-09 | 2012-11-20 | Enanta Pharmaceuticals, Inc. | Linked dibenzimidazole antivirals |
| US8188132B2 (en) | 2009-02-17 | 2012-05-29 | Enanta Pharmaceuticals, Inc. | Linked dibenzimidazole derivatives |
| US8242156B2 (en) * | 2009-02-17 | 2012-08-14 | Enanta Pharmaceuticals, Inc. | Linked dibenzimidazole derivatives |
| WO2010099432A2 (en) * | 2009-02-26 | 2010-09-02 | The Johns Hopkins University | Recognition of cyp2e1 epitopes |
| US9765087B2 (en) | 2009-02-27 | 2017-09-19 | Enanta Pharmaceuticals, Inc. | Benzimidazole derivatives |
| US8101643B2 (en) * | 2009-02-27 | 2012-01-24 | Enanta Pharmaceuticals, Inc. | Benzimidazole derivatives |
| US8673954B2 (en) | 2009-02-27 | 2014-03-18 | Enanta Pharmaceuticals, Inc. | Benzimidazole derivatives |
| US20110182850A1 (en) | 2009-04-10 | 2011-07-28 | Trixi Brandl | Organic compounds and their uses |
| US8512690B2 (en) | 2009-04-10 | 2013-08-20 | Novartis Ag | Derivatised proline containing peptide compounds as protease inhibitors |
| WO2010120935A1 (en) * | 2009-04-15 | 2010-10-21 | Abbott Laboratories | Anti-viral compounds |
| TWI468160B (zh) * | 2009-04-25 | 2015-01-11 | Hoffmann La Roche | 增進藥物動力學之方法 |
| US8716454B2 (en) | 2009-06-11 | 2014-05-06 | Abbvie Inc. | Solid compositions |
| US9394279B2 (en) | 2009-06-11 | 2016-07-19 | Abbvie Inc. | Anti-viral compounds |
| RS53856B1 (sr) * | 2009-06-11 | 2015-08-31 | Abbvie Bahamas Ltd. | Heterociklična jedinjenja kao inhibitori hepatitis c virusa |
| US8937150B2 (en) | 2009-06-11 | 2015-01-20 | Abbvie Inc. | Anti-viral compounds |
| US8221737B2 (en) | 2009-06-16 | 2012-07-17 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| WO2010148006A1 (en) * | 2009-06-16 | 2010-12-23 | Enanta Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
| US8609648B2 (en) | 2009-07-02 | 2013-12-17 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8703938B2 (en) * | 2009-09-11 | 2014-04-22 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8822700B2 (en) * | 2009-09-11 | 2014-09-02 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8759332B2 (en) * | 2009-09-11 | 2014-06-24 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8815928B2 (en) | 2009-09-11 | 2014-08-26 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| WO2011031904A1 (en) * | 2009-09-11 | 2011-03-17 | Enanta Pharmaceuticals, Inc | Hepatitis c virus inhibitors |
| US8927709B2 (en) * | 2009-09-11 | 2015-01-06 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8653070B2 (en) * | 2009-12-14 | 2014-02-18 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| WO2011091417A1 (en) | 2010-01-25 | 2011-07-28 | Enanta Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
| US8933110B2 (en) | 2010-01-25 | 2015-01-13 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8178531B2 (en) * | 2010-02-23 | 2012-05-15 | Enanta Pharmaceuticals, Inc. | Antiviral agents |
| US8623814B2 (en) * | 2010-02-23 | 2014-01-07 | Enanta Pharmaceuticals, Inc. | Antiviral agents |
| US9060971B2 (en) * | 2010-03-04 | 2015-06-23 | Enanta Pharmaceuticals, Inc. | Combination pharmaceutical agents as inhibitors of HCV replication |
| EP2609923B1 (en) | 2010-03-31 | 2017-05-24 | Gilead Pharmasset LLC | Process for the crystallisation of (s)-isopropyl 2-(((s)-(perfluorophenoxy)(phenoxy)phosphoryl)amino)propanoate |
| US9127021B2 (en) | 2010-04-09 | 2015-09-08 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| EP2575819A4 (en) | 2010-06-04 | 2013-11-27 | Enanta Pharm Inc | INHIBITORS OF HEPATITIS C VIRUS |
| NZ605440A (en) | 2010-06-10 | 2014-05-30 | Abbvie Bahamas Ltd | Solid compositions comprising an hcv inhibitor |
| EP2603080A4 (en) | 2010-08-12 | 2014-01-22 | Enanta Pharm Inc | HEPATITIS C-VIRUS HEMMER |
| EA201390532A1 (ru) | 2010-10-08 | 2013-09-30 | Новартис Аг | Композиции сульфамидых ингибиторов ns3, содержащие витамин е |
| WO2012075140A1 (en) | 2010-11-30 | 2012-06-07 | Pharmasset, Inc. | Compounds |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| JP5669984B2 (ja) | 2011-05-18 | 2015-02-18 | エナンタ ファーマシューティカルズ インコーポレイテッド | ５−アザスピロ［２．４］ヘプタン−６−カルボン酸およびその誘導体の製造方法 |
| RU2013155713A (ru) | 2011-07-06 | 2015-08-20 | Профибрикс Бв | Составы для лечения ран |
| UA116087C2 (uk) | 2011-09-16 | 2018-02-12 | Гіліад Фармассет Елелсі | Композиція для лікування вірусу гепатиту c |
| BR112014008616A2 (pt) * | 2011-10-10 | 2017-04-18 | Hoffmann La Roche | compostos antivirais |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| CN104023726A (zh) | 2011-10-21 | 2014-09-03 | 艾伯维公司 | 用于治疗hcv的一种或多种daa的联合治疗(例如，与abt-072或abt-333) |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| DE112012003510T5 (de) | 2011-10-21 | 2015-03-19 | Abbvie Inc. | Verfahren zur Behandlung von HCV umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin aber nicht Interferon |
| US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
| US9034832B2 (en) | 2011-12-29 | 2015-05-19 | Abbvie Inc. | Solid compositions |
| MY168778A (en) * | 2012-05-18 | 2018-12-04 | Replicor Inc | Oligonucleotide chelate complex-polypeptide compositions and methods |
| CA2876496A1 (en) * | 2012-06-27 | 2014-01-03 | Abbvie Inc. | Methods for treating hcv |
| CN104144682A (zh) | 2013-01-31 | 2014-11-12 | 吉利德法莫赛特有限责任公司 | 两个抗病毒化合物的联用制剂 |
| US11484534B2 (en) | 2013-03-14 | 2022-11-01 | Abbvie Inc. | Methods for treating HCV |
| WO2015103490A1 (en) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Solid antiviral dosage forms |
| CN113274386A (zh) * | 2015-06-30 | 2021-08-20 | 艾格集团国际公司 | 氯喹和克立咪唑化合物用于治疗炎症和癌症的用途 |
| EA201892448A1 (ru) | 2016-04-28 | 2019-06-28 | Эмори Юниверсити | Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения |
| CA3139291A1 (en) * | 2019-07-18 | 2021-01-21 | Jacky Vonderscher | Method for decreasing adverse-effects of interferon |
| WO2024223797A1 (en) | 2023-04-28 | 2024-10-31 | Institut National de la Santé et de la Recherche Médicale | Use of cyp3a4 inhibitors for the treatment of hepatitis d virus (hdv) infections |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2779653B1 (fr) * | 1998-06-11 | 2002-12-20 | Inst Nat Sante Rech Med | Utilisation de composes modulateurs du proteasome en therapie |
| SV2003000617A (es) * | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
| WO2002100851A2 (en) * | 2001-06-11 | 2002-12-19 | Shire Biochem Inc. | Thiophene derivatives as antiviral agents for flavivirus infection |
| TW200510391A (en) * | 2003-04-11 | 2005-03-16 | Vertex Pharma | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
| US7109172B2 (en) * | 2003-07-18 | 2006-09-19 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
| PE20050374A1 (es) * | 2003-09-05 | 2005-05-30 | Vertex Pharma | Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc |
| EP2361925A1 (en) * | 2003-10-10 | 2011-08-31 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
| AR055395A1 (es) * | 2005-08-26 | 2007-08-22 | Vertex Pharma | Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c |
-
2004
- 2004-10-27 RU RU2006118359/15A patent/RU2006118359A/ru not_active Application Discontinuation
- 2004-10-27 AU AU2004285503A patent/AU2004285503A1/en not_active Abandoned
- 2004-10-27 DE DE602004018363T patent/DE602004018363D1/de not_active Expired - Lifetime
- 2004-10-27 AT AT04810032T patent/ATE416789T1/de active
- 2004-10-27 US US10/974,538 patent/US20060003942A1/en not_active Abandoned
- 2004-10-27 DK DK04810032T patent/DK1677827T3/da active
- 2004-10-27 WO PCT/US2004/035549 patent/WO2005042020A2/en not_active Ceased
- 2004-10-27 ES ES04810032T patent/ES2319775T3/es not_active Expired - Lifetime
- 2004-10-27 SI SI200431034T patent/SI1677827T1/sl unknown
- 2004-10-27 KR KR1020067010372A patent/KR20060120162A/ko not_active Ceased
- 2004-10-27 CA CA002543696A patent/CA2543696A1/en not_active Abandoned
- 2004-10-27 EP EP04810032A patent/EP1677827B1/en not_active Expired - Lifetime
- 2004-10-27 CN CNA200480037505XA patent/CN1893978A/zh active Pending
- 2004-10-27 BR BRPI0415935-7A patent/BRPI0415935A/pt not_active IP Right Cessation
- 2004-10-27 MX MXPA06004723A patent/MXPA06004723A/es active IP Right Grant
- 2004-10-27 PL PL04810032T patent/PL1677827T3/pl unknown
- 2004-10-27 PT PT04810032T patent/PT1677827E/pt unknown
- 2004-10-27 JP JP2006538195A patent/JP2007509950A/ja active Pending
- 2004-10-27 ZA ZA200603863A patent/ZA200603863B/en unknown
-
2006
- 2006-04-26 IL IL175211A patent/IL175211A0/en unknown
- 2006-05-29 NO NO20062428A patent/NO20062428L/no not_active Application Discontinuation
-
2009
- 2009-03-10 CY CY20091100274T patent/CY1110176T1/el unknown
- 2009-06-23 US US12/490,196 patent/US20100015090A1/en not_active Abandoned
-
2012
- 2012-01-23 US US13/355,638 patent/US20120114604A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DK1677827T3 (da) | 2009-03-30 |
| WO2005042020A2 (en) | 2005-05-12 |
| EP1677827B1 (en) | 2008-12-10 |
| US20120114604A1 (en) | 2012-05-10 |
| PT1677827E (pt) | 2009-03-13 |
| JP2007509950A (ja) | 2007-04-19 |
| WO2005042020A3 (en) | 2005-06-23 |
| ES2319775T3 (es) | 2009-05-12 |
| ATE416789T1 (de) | 2008-12-15 |
| SI1677827T1 (sl) | 2009-06-30 |
| CA2543696A1 (en) | 2005-05-12 |
| IL175211A0 (en) | 2006-09-05 |
| DE602004018363D1 (de) | 2009-01-22 |
| BRPI0415935A (pt) | 2007-01-02 |
| EP1677827A2 (en) | 2006-07-12 |
| AU2004285503A1 (en) | 2005-05-12 |
| CY1110176T1 (el) | 2015-01-14 |
| PL1677827T3 (pl) | 2009-06-30 |
| KR20060120162A (ko) | 2006-11-24 |
| US20100015090A1 (en) | 2010-01-21 |
| ZA200603863B (en) | 2007-11-28 |
| CN1893978A (zh) | 2007-01-10 |
| US20060003942A1 (en) | 2006-01-05 |
| MXPA06004723A (es) | 2006-07-05 |
| NO20062428L (no) | 2006-05-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2006118359A (ru) | Комбинации для лечения вирусного гепатита с (hcv) | |
| JP2007509950A5 (ru) | ||
| RU2010135497A (ru) | Ингибирование протеазы ns3-ns4 вируса hcv | |
| RU2011142651A (ru) | Способы улучшения фармакокинетики | |
| TW200612898A (en) | Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same | |
| IS7531A (is) | Skiptitengdir sýklóalkýl P1' lifrarbólgu C-veirutálmar | |
| JP2013521279A5 (ru) | ||
| NO20044897L (no) | Hepatitt C virus inhibitorer | |
| EP2368900A3 (en) | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease | |
| WO2005077969A3 (en) | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease | |
| WO2004014313A3 (en) | Combination pharmaceutical agents as inhibitors of hcv replication | |
| WO2005037860A3 (en) | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease | |
| EP1506000A4 (en) | HETEROCYCLIC SULPHONAMIDE HEPATITIS C VIRUS HEMMER | |
| ECSP077217A (es) | Inhibidores de proteasa peptidomimeticos | |
| WO2003087092A3 (en) | Inhibitors of serine proteases, particularly hepatitis c virus ns3 - ns4 protease | |
| CA2573207A1 (en) | Use of a combination of cyclosporin and pegylated interferons for treating hepatitis c (hcv) | |
| Amblard et al. | Synthesis and evaluation of non-dimeric HCV NS5A inhibitors | |
| WO2008046860A3 (en) | Bioavailable combinations for hcv treatment | |
| Reviriego | Asunaprevir | |
| CA2474035A1 (en) | Macrocyclic peptides active against the hepatitis c virus | |
| HK1098357A (en) | Combinations for hcv treatment | |
| NZ600527A (en) | Antiviral compounds | |
| TH124102A (th) | สารยับยั้งเปปไทโดไมเมทิคโปรทีเอส |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA94 | Acknowledgement of application withdrawn (non-payment of fees) |
Effective date: 20101202 |